Saliva Diagnostic Systems
This article was originally published in The Gray Sheet
Executive Summary
Merger with Chembio Diagnostic Systems under a letter of intent would result in SDS shareholders retaining about 25% of the resulting company. While SDS has been unsuccessful in developing efficient manufacturing, CDS has extensive R&D and manufacturing experience in the rapid test field, SDS explains. Awaiting approval by the firms' board of directors and shareholders, an interim manufacturing and supply agreement has been established for SDS products